{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T01:00:21Z","timestamp":1781917221729,"version":"3.54.5"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T00:00:00Z","timestamp":1664409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T00:00:00Z","timestamp":1664409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-022-01805-w","type":"journal-article","created":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T20:03:15Z","timestamp":1664481795000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Evaluation of lung adverse events with trastuzumab using the Japanese pharmacovigilance database"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4680-5133","authenticated-orcid":false,"given":"Yuko","family":"Kanbayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayako","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misui","family":"Kashiwagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitomi","family":"Akiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,29]]},"reference":[{"key":"1805_CR1","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783\u201392. https:\/\/doi.org\/10.1056\/NEJM200103153441101.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"1805_CR2","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1093\/annonc\/12.suppl_1.S57","volume":"12","author":"W Eiermann","year":"2001","unstructured":"Eiermann W, International Herceptin Study Group. Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: pivotal trial data. Ann Oncol. 2001;12(Suppl 1):S57-62.","journal-title":"Ann Oncol"},{"key":"1805_CR3","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1200\/JCO.2002.20.3.719","volume":"20","author":"CL Vogel","year":"2002","unstructured":"Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:719\u201326. https:\/\/doi.org\/10.1200\/JCO.2002.20.3.719.","journal-title":"J Clin Oncol"},{"key":"1805_CR4","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687\u201397. https:\/\/doi.org\/10.1016\/S0140-6736(10)61121-X.","journal-title":"Lancet"},{"key":"1805_CR5","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/S1470-2045(18)30904-5","volume":"20","author":"F Meric-Bernstam","year":"2019","unstructured":"Meric-Bernstam F, Hurwitz H, Raghav KPS, McWilliams RR, Fakih M, VanderWalde A, et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2019;20:518\u201330. https:\/\/doi.org\/10.1016\/S1470-2045(18)30904-5.","journal-title":"Lancet Oncol"},{"key":"1805_CR6","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1200\/JCO.18.00545","volume":"37","author":"H Takahashi","year":"2019","unstructured":"Takahashi H, Tada Y, Saotome T, Akazawa K, Ojiri H, Fushimi C, et al. Phase II trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2-positive salivary duct carcinoma. J Clin Oncol. 2019;37:125\u201334. https:\/\/doi.org\/10.1200\/JCO.18.00545.","journal-title":"J Clin Oncol"},{"key":"1805_CR7","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.ctrv.2010.09.001","volume":"37","author":"T Chen","year":"2011","unstructured":"Chen T, Xu T, Li Y, Liang C, Chen J, Lu Y, et al. Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis. Cancer Treat Rev. 2011;37:312\u201320. https:\/\/doi.org\/10.1016\/j.ctrv.2010.09.001.","journal-title":"Cancer Treat Rev"},{"key":"1805_CR8","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1634\/theoncologist.2013-0286","volume":"19","author":"LM Thompson","year":"2014","unstructured":"Thompson LM, Eckmann K, Boster BL, Hess KR, Michaud LB, Esteva FJ, et al. Incidence, risk factors, and management of infusion-related reactions in breast cancer patients receiving trastuzumab. Oncologist. 2014;19:228\u201334. https:\/\/doi.org\/10.1634\/theoncologist.2013-0286.","journal-title":"Oncologist"},{"key":"1805_CR9","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1634\/theoncologist.2015-0424","volume":"21","author":"HD Long","year":"2016","unstructured":"Long HD, Lin YE, Zhang JJ, Zhong WZ, Zheng RN. Risk of congestive heart failure in early breast cancer patients undergoing adjuvant treatment with trastuzumab: a meta-analysis. Oncologist. 2016;21:547\u201354. https:\/\/doi.org\/10.1634\/theoncologist.2015-0424.","journal-title":"Oncologist"},{"key":"1805_CR10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ejca.2015.09.012","volume":"52","author":"M Rossi","year":"2016","unstructured":"Rossi M, Carioli G, Bonifazi M, Zambelli A, Franchi M, Moja L, et al. Trastuzumab for HER2+ metastatic breast cancer in clinical practice: cardiotoxicity and overall survival. Eur J Cancer. 2016;52:41\u20139. https:\/\/doi.org\/10.1016\/j.ejca.2015.09.012.","journal-title":"Eur J Cancer"},{"key":"1805_CR11","doi-asserted-by":"publisher","first-page":"3991","DOI":"10.1200\/JCO.2007.10.9777","volume":"25","author":"JR Carver","year":"2007","unstructured":"Carver JR, Shapiro CL, Ng A, Jacobs L, Schwartz C, Virgo KS, et al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol. 2007;25:3991\u20134008. https:\/\/doi.org\/10.1200\/JCO.2007.10.9777.","journal-title":"J Clin Oncol"},{"key":"1805_CR12","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1016\/j.ejca.2015.05.028","volume":"51","author":"X Pivot","year":"2015","unstructured":"Pivot X, Suter T, Nabholtz JM, Pierga JY, Espie M, Lortholary A, et al. Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III study. Eur J Cancer. 2015;51:1660\u20136. https:\/\/doi.org\/10.1016\/j.ejca.2015.05.028.","journal-title":"Eur J Cancer"},{"key":"1805_CR13","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1177\/1060028019865870","volume":"53","author":"M Uchida","year":"2019","unstructured":"Uchida M, Kondo Y, Suzuki S, Hosohata K. Evaluation of acute kidney injury associated with anticancer drugs used in gastric cancer in the Japanese Adverse Drug Event Report database. Ann Pharmacother. 2019;53:1200\u20136. https:\/\/doi.org\/10.1177\/1060028019865870.","journal-title":"Ann Pharmacother"},{"key":"1805_CR14","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1248\/bpb.b19-00105","volume":"42","author":"H Sugawara","year":"2019","unstructured":"Sugawara H, Uchida M, Suzuki S, Suga Y, Uesawa Y, Nakagawa T, et al. Analyses of respiratory depression associated with opioids in cancer patients based on the Japanese Adverse Drug Event report database. Biol Pharm Bull. 2019;42:1185\u201391. https:\/\/doi.org\/10.1248\/bpb.b19-00105.","journal-title":"Biol Pharm Bull"},{"key":"1805_CR15","doi-asserted-by":"publisher","first-page":"16","DOI":"10.18433\/jpps31597","volume":"24","author":"M Uchida","year":"2021","unstructured":"Uchida M, Kawashiri T, Maegawa N, Takano A, Hosohata K, Uesawa Y. Pharmacovigilance evaluation of bendamustine-related skin disorders using the Japanese Adverse Drug Event Report database. J Pharm Sci. 2021;24:16\u201322. https:\/\/doi.org\/10.18433\/jpps31597.","journal-title":"J Pharm Sci"},{"key":"1805_CR16","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1159\/000519687","volume":"100","author":"S Nakao","year":"2022","unstructured":"Nakao S, Uchida M, Satoki A, Okamoto K, Uesawa Y, Shimizu T. Evaluation of cardiac adverse events associated with carfilzomib using a Japanese real-world database. Oncology. 2022;100:60\u20134. https:\/\/doi.org\/10.1159\/000519687.","journal-title":"Oncology"},{"key":"1805_CR17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP van Puijenbroek","year":"2002","unstructured":"van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11:3\u201310. https:\/\/doi.org\/10.1002\/pds.668.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1805_CR18","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1248\/bpbb19-00156","volume":"42","author":"G Ando","year":"2019","unstructured":"Ando G, Taguchi K, Enoki Y, Yokoyama Y, Kizu J, Matsumoto K. Evaluation of the expression time of ganciclovir-induced adverse events using JADER and FAERS. Biol Pharm Bull. 2019;42:1799\u2013804. https:\/\/doi.org\/10.1248\/bpbb19-00156.","journal-title":"Biol Pharm Bull"},{"key":"1805_CR19","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s40264-013-0061-7","volume":"36","author":"O Sauzet","year":"2013","unstructured":"Sauzet O, Carvajal A, Escudero A, Molokhia M, Cornelius VR. Illustration of the Weibull shape parameter signal detection tool using electronic healthcare record data. Drug Saf. 2013;36:995\u20131006. https:\/\/doi.org\/10.1007\/s40264-013-0061-7.","journal-title":"Drug Saf"},{"key":"1805_CR20","unstructured":"Hirooka T, Yamada M (2012) Evaluation of risk of adverse reaction using PMDA \u2018Adverse Drug Reaction Database. Database SAS User Groups Ronbun-syu"},{"key":"1805_CR21","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3892\/mco.2016.1113","volume":"6","author":"A Sugaya","year":"2017","unstructured":"Sugaya A, Ishiguro S, Mitsuhashi S, Abe M, Hashimoto I, Kaburagi T, et al. Interstitial lung disease associated with trastuzumab monotherapy: a report of 3 cases. Mol Clin Oncol. 2017;6:229\u201332. https:\/\/doi.org\/10.3892\/mco.2016.1113.","journal-title":"Mol Clin Oncol"},{"key":"1805_CR22","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1159\/000326063","volume":"4","author":"O Abulkhair","year":"2011","unstructured":"Abulkhair O, El Melouk W. Delayed paclitaxel-trastuzumab-induced interstitial pneumonitis in breast cancer. Case Rep Oncol. 2011;4:186\u201391. https:\/\/doi.org\/10.1159\/000326063.","journal-title":"Case Rep Oncol"},{"key":"1805_CR23","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s10549-020-05754-8","volume":"183","author":"MD Hackshaw","year":"2020","unstructured":"Hackshaw MD, Danysh HE, Singh J, Ritchey ME, Ladner A, Taitt C, et al. Incidence of pneumonitis\/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2020;183:23\u201339. https:\/\/doi.org\/10.1007\/s10549-020-05754-8.","journal-title":"Breast Cancer Res Treat"},{"key":"1805_CR24","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1517\/17425255.2015.1080687","volume":"11","author":"LA Teuwen","year":"2015","unstructured":"Teuwen LA, Van den Mooter T, Dirix L. Management of pulmonary toxicity associated with targeted anticancer therapies. Expert Opin Drug Metab Toxicol. 2015;11:1695\u2013707. https:\/\/doi.org\/10.1517\/17425255.2015.1080687.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1805_CR25","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","volume":"382","author":"S Modi","year":"2020","unstructured":"Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382:610\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1914510.","journal-title":"N Engl J Med"},{"key":"1805_CR26","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","volume":"382","author":"K Shitara","year":"2020","unstructured":"Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382:2419\u201330. https:\/\/doi.org\/10.1056\/NEJMoa2004413.","journal-title":"N Engl J Med"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-022-01805-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-022-01805-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-022-01805-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T20:32:29Z","timestamp":1667334749000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-022-01805-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,29]]},"references-count":26,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1805"],"URL":"https:\/\/doi.org\/10.1007\/s12032-022-01805-w","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,29]]},"assertion":[{"value":"21 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Ethics approval was not sought for this study; given the database-related, observational design without direct involvement of any research subjects. All results were obtained from data openly available online from the PMDA website (). All data from the JADER database were fully anonymized by the relevant regulatory authority before we accessed them. Thus, all methods were performed in accordance with the relevant guidelines and regulations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"219"}}